Anavex Advances Drug Candidates for Treatment of Epilepsy

Results in epilepsy animal models demonstrate that ANAVEX 2-73 and its active metabolite ANAVEX 19-144 have potent anticonvulsant, anti-amnesic and neuroprotective properties Geneva, Switzerland — December 6, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced promising developments with ANAVEX 2-73 and ANAVEX 19-144, the company’s lead drug candidates to treat epilepsy. During…

Anavex Life Sciences Engages Primoris Group to Provide Investor Relations Services

Geneva, Switzerland — November 2, 2007 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCBB: AVXL) is pleased to announce that it has engaged Primoris Group Inc. to provide investor relations services to the Company.  Primoris Group is a full-service investor relations firm based in Toronto,Canada.Primoris Group will implement a communications program to support…

Annual General Meeting of the Shareholders of Anavex Life Sciences Corp.

The Annual General Meeting of Anavex Life Sciences Corp. shareholders was held on May 25, 2007 in Geneva, Switzerland Geneva, Switzerland — June 5, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB:AVXL) a biopharmaceutical company, announced the results of its recently held Annual General Meeting. At the Annual General Meeting shareholders  elected  Dr. Panos Kontzalis, Mr.…

Preclinical Data of ANAVEX 1-41 and ANAVEX 2-73 Show Highly Potent Anti-Amnesic and Neuroprotective Activity Against Amyloid Beta (25-35) Peptide Toxicity in Alzheimer’s Disease (AD) Animal Models

Data on Anavex’s sigma-ligands ANAVEX 1-41 and ANAVEX 2-73 was presented in a poster at the 8e Colloque de la Societe des Neurosciences Meeting being held in Montpellier, France (Abstract D.30) May 22, 2007 Geneva, Switzerland — May 23, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) a biopharmaceutical company, today announced that…

Dr. Jean Jacques Bourguignon Joins Anavex Life Sciences Corp. Scientific Team

Geneva, Switzerland — April 16, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) a biopharmaceutical company, today announced that Jean Jacques Bourguignon, Ph.D., has joined the company’s scientific team and has been appointed a member of the Scientific Committee. Dr. Bourguignon brings 30 years of solid experience in the field of medicinal chemistry…

Anavex Life Sciences Corp. Announces Research Agreement with University of Paris 5-Rene Descartes

Geneva, Switzerland — April 2, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL), a biopharmaceutical company, announced today that it has entered into a research agreement with the department of Pharmacology and Biological Sciences at Paris 5 University-Rene Descartes, France, to investigate the neuroprotective action of Anavex’s tetrahydrofuranic compound ANAVEX 19-144 (AE37Met) in…

Anavex Life Sciences Corp. Announces its Preclinical Pipeline of Novel Oncology Therapies

Geneva, Switzerland — February 12, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) announces its strategic vision for growth by discovering and developing cutting-edge drugs against solid tumors. The Company’s innovative drug discovery and development programs have helped build a strong pipeline that targets a wide range of solid tumors, including colorectal, prostate,…

Anavex Life Sciences Corp. Appoints VP Business Development and VP Strategic Planning

Geneva, Switzerland — February 07, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that Ms. Angela Vernadaki and Dr. George Kalkanis have been appointed as Officers of the Company. Ms. Vernadaki, appointed as VP Business Development, brings more than ten years of experience in marketing, sales, business development and entrepreneurship in the…

Anavex Life Sciences Corp. Outlines its Central Nervous System (CNS) Portfolio of Novel Therapeutics

Geneva, Switzerland — February 01, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces its strategic vision for growth by discovering and developing cutting-edge drugs against neurological diseases. The Company’s innovative drug discovery and development programs have helped build a strong pipeline that targets a range of serious neurological diseases, including Alzheimer’s Disease…

Anavex Life Sciences Corp. Acquires a Portfolio of Patents and Appoints Dr. Alexandre Vamvakides as CSO and Director

Geneva, Switzerland — January 31, 2007 — Anavex Life Sciences Corp. (OTCBB: AVXL) (the “Company”) announces that it has acquired a portfolio of three patents and one patent application covering drug candidates indented to be further developed through commercialization targeting the areas of neurological diseases and cancer. The patents were assigned by Dr. Alexandre Vamvakides,…